# Genenta Science S.p.A.: overview GNTA · Nasdaq · CIK 1838716 · [Healthcare](/sectors/healthcare.md) Pages: [Overview](/companies/gnta.md) · [Financials](/companies/gnta/financials.md) · [Filings](/companies/gnta/filings.md) · [Insiders](/companies/gnta/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.37)](/filings/0001493152-24-011999.md) | [(0.47)](/filings/0001641172-25-001207.md) | [(0.64)](/filings/0001493152-26-014387.md) | [(0.49)](/filings/0001493152-26-014387.md) | [(0.33)](/filings/0001493152-26-014387.md) | | Free cash flow | $m | [(7.0)](/filings/0001493152-24-011999.md) | [(7.4)](/filings/0001641172-25-001207.md) | [(11.2)](/filings/0001493152-26-014387.md) | [(6.2)](/filings/0001493152-26-014387.md) | [(6.9)](/filings/0001493152-26-014387.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/gnta/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Eurizon Capital SGR S.p.A.](/funds/2107286.md) | 2026-06-30 | $662.4k | 360,000 | | Unchanged | | [Allianz SE](/funds/1127508.md) | 2026-06-30 | $430.7k | 234,050 | | Unchanged | | [SmartHarvest Portfolios, LLC](/funds/2066604.md) | 2026-06-30 | $80.7k | 43,856 | | Reduced −90,591 | | [Simplicity Wealth,LLC](/funds/1913243.md) | 2026-06-30 | $34.2k | 18,590 | | Added +6,379 | | [Ground Swell Capital, LLC](/funds/1534450.md) | 2026-06-30 | $26.4k | 14,374 | | New +14,374 | | [GAMMA Investing LLC](/funds/2010235.md) | 2026-06-30 | $18.1k | 9,863 | | Reduced −4,425 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $5.6k | 3,027 | | Reduced −80 | | [Virtu Financial LLC](/funds/1533964.md) | 2026-06-30 | $68 | 36,913 | | New +36,913 | | [Farther Finance Advisors, LLC](/funds/1992825.md) | 2026-06-30 | $6 | 3 | | Unchanged | ## Recent filings [All 118 filings](/companies/gnta/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 20:05 ET | [6-K](/filings/0001493152-26-048095.md) | Report of a foreign private issuer, period 2026-10-22 | 0001493152-26-048095 | | 2026-10-21 | 20:05 ET | [6-K](/filings/0001493152-26-047888.md) | Report of a foreign private issuer, period 2026-10-21 | 0001493152-26-047888 | | 2026-10-13 | 20:05 ET | [6-K](/filings/0001493152-26-046816.md) | Report of a foreign private issuer, period 2026-10-13 | 0001493152-26-046816 | | 2026-10-07 | 20:05 ET | [6-K](/filings/0001493152-26-046136.md) | Report of a foreign private issuer, period 2026-10-07 | 0001493152-26-046136 | | 2026-10-02 | 19:34 ET | [SCHEDULE 13D/A](/filings/0001493152-26-045500.md) | Ownership report, active investor, amended | 0001493152-26-045500 | | 2026-09-11 | 20:05 ET | [6-K](/filings/0001493152-26-042377.md) | Report of a foreign private issuer, period 2026-09-11 | 0001493152-26-042377 | | 2026-09-02 | 21:42 ET | [6-K](/filings/0001493152-26-041066.md) | Report of a foreign private issuer, period 2026-09-01 | 0001493152-26-041066 | | 2026-07-31 | 20:05 ET | [6-K](/filings/0001493152-26-035626.md) | Report of a foreign private issuer, period 2026-07-31 | 0001493152-26-035626 | | 2026-07-14 | 20:04 ET | [6-K](/filings/0001493152-26-033176.md) | Report of a foreign private issuer, period 2026-07-14 | 0001493152-26-033176 | | 2026-07-01 | 20:09 ET | [6-K](/filings/0001493152-26-031546.md) | Report of a foreign private issuer, period 2026-07-01 | 0001493152-26-031546 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-014387.md), filed Apr 1, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1838716 - Tickers: GNTA - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: L6 - Filer category: Non-accelerated filer
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.